Archives of Pediatric Infectious Diseases

Published by: Kowsar

Truncated D Protein as a New Vaccine Candidate Against Nontypeable Haemophilus influenza

Ava Behrouzi 1 , 2 , Saeid Bouzari 2 , 3 , Mana Oloomi 2 , 3 , Abolfazl Fateh 1 , 2 , Farzam Vaziri 1 , 2 , Parviz Afrough 1 , 2 , Seyed Davar Siadat 1 , 2 , * and Atefeh Davoudi Vijeh Motlagh 4
Authors Information
1 Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran
2 Microbiology Research Center (MRC), Pasteur Institute of Iran, Tehran, Iran
3 Department of Molecular Biology, Pasteur Institute of Iran, Tehran, Iran
4 Immunogenetics Research Center, Mazandaran University of Medical Sciences, Sari, Iran
Article information
  • Archives of Pediatric Infectious Diseases: April 2018, 6 (2); e12062
  • Published Online: March 13, 2018
  • Article Type: Research Article
  • Received: January 7, 2017
  • Revised: April 30, 2017
  • Accepted: September 19, 2017
  • DOI: 10.5812/pedinfect.12062

To Cite: Behrouzi A, Bouzari S, Oloomi M, Fateh A, Vaziri F, et al. Truncated D Protein as a New Vaccine Candidate Against Nontypeable Haemophilus influenza, Arch Pediatr Infect Dis. 2018 ;6(2):e12062. doi: 10.5812/pedinfect.12062.

Abstract
© 2018, Archives of Pediatric Infectious Diseases. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnote
References
  • 1. Kelly DF, Moxon ER, Pollard AJ. Haemophilus influenzae type b conjugate vaccines. Immunology. 2004;113(2):163-74. doi: 10.1111/j.1365-2567.2004.01971.x. [PubMed: 15379976].
  • 2. Falugi F, Petracca R, Mariani M, Luzzi E, Mancianti S, Carinci V, et al. Rationally designed strings of promiscuous CD4(+) T cell epitopes provide help to Haemophilus influenzae type b oligosaccharide: a model for new conjugate vaccines. Eur J Immunol. 2001;31(12):3816-24. doi: 10.1002/1521-4141(200112)31:12<3816::AID-IMMU3816>3.0.CO;2-K. [PubMed: 11745403].
  • 3. Rocha N, Neefjes J. MHC class II molecules on the move for successful antigen presentation. EMBO J. 2008;27(1):1-5. doi: 10.1038/sj.emboj.7601945. [PubMed: 18046453].
  • 4. Giebink GS. The microbiology of otitis media. Pediatr Infect Dis J. 1989;8(1 Suppl):S18-20. doi: 10.1097/00006454-198901001-00008. [PubMed: 2648288].
  • 5. Nelson JD. Changing trends in the microbiology and management of acute otitis media and sinusitis. Pediatr Infect Dis. 1986;5(6):749-53. [PubMed: 3797319].
  • 6. Krasan GP, Cutter D, Block SL, St Geme J3. Adhesin expression in matched nasopharyngeal and middle ear isolates of nontypeable Haemophilus influenzae from children with acute otitis media. Infect Immun. 1999;67(1):449-54. [PubMed: 9864255].
  • 7. Farley MM, Stephens DS, Brachman PJ, Harvey RC, Smith JD, Wenger JD. Invasive Haemophilus influenzae disease in adults. A prospective, population-based surveillance. CDC Meningitis Surveillance Group. Ann Intern Med. 1992;116(10):806-12. doi: 10.7326/0003-4819-116-10-806. [PubMed: 1314530].
  • 8. Mason EJ, Kaplan SL, Lamberth LB, Hinds DB, Kvernland SJ, Loiselle EM, et al. Serotype and ampicillin susceptibility of Haemophilus influenzae causing systemic infections in children: 3 years of experience. J Clin Microbiol. 1982;15(4):543-6. [PubMed: 6978349].
  • 9. Sansoni A, Rappuoli R, Viti S, Costantino P, Fanti O, Cellesi C. Immunity to Haemophilus influenzae type b on sample population from central Italy. Vaccine. 1992;10(9):627-30. doi: 10.1016/0264-410X(92)90445-P. [PubMed: 1502841].
  • 10. Berthet F, Prehn A, Suter R, Ethevenaux C, Seger RA. Protective immunogenicity of Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in children who failed to respond to prior invasive H. influenzae type b disease. Pediatr Allergy Immunol. 1998;9(3):156-60. doi: 10.1111/j.1399-3038.1998.tb00363.x. [PubMed: 9814731].
  • 11. Greenberg DP, Vadheim CM, Bordenave N, Ziontz L, Christenson P, Waterman SH, et al. Protective efficacy of Haemophilus influenzae type b polysaccharide and conjugate vaccines in children 18 months of age and older. JAMA. 1991;265(8):987-92. [PubMed: 1992212].
  • 12. Heath PT, Bowen-Morris J, Griffiths D, Griffiths H, Crook DW, Moxon ER. Antibody persistence and Haemophilus influenzae type b carriage after infant immunisation with PRP-T. Arch Dis Child. 1997;77(6):488-92. doi: 10.1136/adc.77.6.488. [PubMed: 9496180].
  • 13. Mariotti S, Teloni R, von Hunolstein C, Romagnoli G, Orefici G, Nisini R. Immunogenicity of anti-Haemophilus influenzae type b CRM197 conjugate following mucosal vaccination with oligodeoxynucleotide containing immunostimulatory sequences as adjuvant. Vaccine. 2002;20(17-18):2229-39. doi: 10.1016/S0264-410X(02)00113-5. [PubMed: 12009277].
  • 14. Ward J, Brenneman G, Letson GW, Heyward WL. Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. The Alaska H. influenzae Vaccine Study Group. N Engl J Med. 1990;323(20):1393-401. doi: 10.1056/NEJM199011153232006. [PubMed: 2233906].
  • 15. Loeb MR, Smith DH. Outer membrane protein composition in disease isolates of Haemophilus influenzae: pathogenic and epidemiological implications. Infect Immun. 1980;30(3):709-17. [PubMed: 6971807].
  • 16. Janson H, Heden LO, Grubb A, Ruan MR, Forsgren A. Protein D, an immunoglobulin D-binding protein of Haemophilus influenzae: cloning, nucleotide sequence, and expression in Escherichia coli. Infect Immun. 1991;59(1):119-25. [PubMed: 1987023].
  • 17. Ruan MR, Akkoyunlu M, Grubb A, Forsgren A. Protein D of Haemophilus influenzae. A novel bacterial surface protein with affinity for human IgD. J Immunol. 1990;145(10):3379-84. [PubMed: 2230124].
  • 18. Larson TJ, Ehrmann M, Boos W. Periplasmic glycerophosphodiester phosphodiesterase of Escherichia coli, a new enzyme of the glp regulon. J Biol Chem. 1983;258(9):5428-32. [PubMed: 6304089].
  • 19. Tommassen J, Eiglmeier K, Cole ST, Overduin P, Larson TJ, Boos W. Characterization of two genes, glpQ and ugpQ, encoding glycerophosphoryl diester phosphodiesterases of Escherichia coli. Mol Gen Genet. 1991;226(1-2):321-7. doi: 10.1007/BF00273621. [PubMed: 1851953].
  • 20. Wu HC, Tokunaga M. Biogenesis of lipoproteins in bacteria. Curr Top Microbiol Immunol. 1986;125:127-57. doi: 10.1007/978-3-642-71251-7_9. [PubMed: 3527576].
  • 21. Ahren IL, Janson H, Forsgren A, Riesbeck K. Protein D expression promotes the adherence and internalization of non-typeable Haemophilus influenzae into human monocytic cells. Microb Pathog. 2001;31(3):151-8. doi: 10.1006/mpat.2001.0456. [PubMed: 11500100].
  • 22. Fan X, Goldfine H, Lysenko E, Weiser JN. The transfer of choline from the host to the bacterial cell surface requires glpQ in Haemophilus influenzae. Mol Microbiol. 2001;41(5):1029-36. doi: 10.1046/j.1365-2958.2001.02571.x. [PubMed: 11555284].
  • 23. Forsgren A, Riesbeck K, Janson H. Protein D of Haemophilus influenzae: a protective nontypeable H. influenzae antigen and a carrier for pneumococcal conjugate vaccines. Clin Infect Dis. 2008;46(5):726-31. doi: 10.1086/527396. [PubMed: 18230042].
  • 24. Janson H, Carl n B, Cervin A, Forsgren A, Magnusdottir AB, Lindberg S, et al. Effects on the ciliated epithelium of protein D-producing and -nonproducing nontypeable Haemophilus influenzae in nasopharyngeal tissue cultures. J Infect Dis. 1999;180(3):737-46. doi: 10.1086/314921. [PubMed: 10438362].
  • 25. Janson H, Melhus A, Hermansson A, Forsgren A. Protein D, the glycerophosphodiester phosphodiesterase from Haemophilus influenzae with affinity for human immunoglobulin D, influences virulence in a rat otitis model. Infect Immun. 1994;62(11):4848-54. [PubMed: 7927765].
  • 26. Munson RJ, Sasaki K. Protein D, a putative immunoglobulin D-binding protein produced by Haemophilus influenzae, is glycerophosphodiester phosphodiesterase. J Bacteriol. 1993;175(14):4569-71. doi: 10.1128/jb.175.14.4569-4571.1993. [PubMed: 8392514].
  • 27. Broome CV. Vaccine efficacy determination. NIPH Ann. 1991;14(2):219-21. discussion 222-4. [PubMed: 1812435].
  • 28. Broome CV, Breiman RF. Pneumococcal vaccine--past, present, and future. N Engl J Med. 1991;325(21):1506-8. doi: 10.1056/NEJM199111213252109. [PubMed: 1944428].
  • 29. Centers for Disease Control and Prevention (CDC). Progress toward eliminating Haemophilus influenzae type b disease among infants and children--United States, 1987-1997. MMWR Morb Mortal Wkly Rep. 1998;47(46):993-8. [PubMed: 9843325].
  • 30. Maroun JA. Haemophilus b conjugate vaccine. CMAJ. 1988;138(11):1031-2. [PubMed: 3370570].
  • 31. St Geme JW. Molecular and cellular determinants of non-typeable Haemophilus influenzae adherence and invasion. Cell Microbiol. 2002;4(4):191-200. doi: 10.1046/j.1462-5822.2002.00180.x. [PubMed: 11952636].
  • 32. Winter LE, Barenkamp SJ. Antibodies specific for the high-molecular-weight adhesion proteins of nontypeable Haemophilus influenzae are opsonophagocytic for both homologous and heterologous strains. Clin Vaccine Immunol. 2006;13(12):1333-42. doi: 10.1128/CVI.00221-06. [PubMed: 17021246].
  • 33. Prymula R, Peeters P, Chrobok V, Kriz P, Novakova E, Kaliskova E, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet. 2006;367(9512):740-8. doi: 10.1016/S0140-6736(06)68304-9. [PubMed: 16517274].
  • 34. Pichichero ME, Kaur R, Casey JR, Sabirov A, Khan MN, Almudevar A. Antibody response to Haemophilus influenzae outer membrane protein D, P6, and OMP26 after nasopharyngeal colonization and acute otitis media in children. Vaccine. 2010;28(44):7184-92. doi: 10.1016/j.vaccine.2010.08.063. [PubMed: 20800701].
  • 35. Clementi CF, Murphy TF. Non-typeable Haemophilus influenzae invasion and persistence in the human respiratory tract. Front Cell Infect Microbiol. 2011;1:1. doi: 10.3389/fcimb.2011.00001. [PubMed: 22919570].
  • 36. Dicko A, Santara G, Mahamar A, Sidibe Y, Barry A, Dicko Y, et al. Safety, reactogenicity and immunogenicity of a booster dose of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children. Hum Vaccin Immunother. 2013;9(2):382-8. doi: 10.4161/hv.22692. [PubMed: 23291945].
  • 37. Marciani DJ. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov Today. 2003;8(20):934-43. doi: 10.1016/S1359-6446(03)02864-2. [PubMed: 14554157].
  • 38. Huleatt JW, Jacobs AR, Tang J, Desai P, Kopp EB, Huang Y, et al. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine. 2007;25(4):763-75. doi: 10.1016/j.vaccine.2006.08.013. [PubMed: 16968658].

Altmetric:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Comments